KM871 monoclonal antibody

Known as: KM871, mAb KM871, monoclonal antibody KM871 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1993-2005
01219932005

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
We conducted an open label dose-escalation phase I trial of chimeric anti-GD3 mAb KM871 in patients with metastatic melanoma… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2002
2002
The chimeric KM871 monoclonal antibody targets the GD3 disialoganglioside antigen and is under investigation for its… (More)
Is this relevant?
2002
2002
The chimeric KM871 monoclonal antibody targets the GD3 disialoganglioside antigen and is under investigation for its… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2001
2001
PURPOSE KM871 is a chimeric monoclonal antibody against the ganglioside antigen GD3, which is highly expressed on melanoma cells… (More)
Is this relevant?
2001
2001
The chimeric monoclonal antibody KM871, directed against the G(D3) antigen, is under evaluation for its potential to target… (More)
  • figure 1
  • figure 3
  • figure 2
  • table 1
  • figure 4
Is this relevant?
2000
2000
KM871 is a chimeric antibody recognizing ganglioside GD3, which is one of the major gangliosides expressed on the cell surface of… (More)
  • table 2
  • figure 1
  • table 1
  • figure 2
  • table 4
Is this relevant?
2000
2000
Several gangliosides such as GM2, GD2, and GD3 have been thought of as target molecules for active or passive immunotherapy of… (More)
Is this relevant?
1993
1993
Ganglioside GD3, which is one of the major gangliosides expressed on the cell surface of human tumors of neuroectodermal origin… (More)
  • figure 2
  • figure 6
  • figure 4
  • figure 7
  • figure 5
Is this relevant?